Last reviewed · How we verify
Quadruple
At a glance
| Generic name | Quadruple |
|---|---|
| Also known as | Quadruple Therapy for H. pylori |
| Sponsor | University of Alberta |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese (PHASE2)
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (PHASE3)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma (PHASE1, PHASE2)
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (PHASE2)
- Local Infiltration Analgesia Versus Quadruple Nerve Blocks in Total Knee Arthroplasty. (NA)
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quadruple CI brief — competitive landscape report
- Quadruple updates RSS · CI watch RSS
- University of Alberta portfolio CI